NCT04063085View on ClinicalTrials.gov

The Assessment of the Use of Anti-Adhesion Agents to Prevent Pelvic Postoperative Adhesions

NACompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

January 5, 2022

Study Completion Date

October 12, 2023

Conditions
Tissue AdhesionGynecologic Surgery
Interventions
DEVICE

PROTAHERE Absorbable Adhesion Barrier

40 mg/ml (4%) cross-linked hyaluronan

DEVICE

Hyalobarrier Gel

Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan

OTHER

No treatment

No anti-adhesion agent applied

DEVICE

Seprafilm Adhesion Barrier

a hyaluronate carboxymethylcellulose-based bioresorbable membrane

DEVICE

Gynecare Interceed (TC7) Absorbable Adhesion Barrier

an oxidized regenerated cellulose absorbable membrane

Trial Locations (1)

Unknown

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

SciVision Biotech Inc.

INDUSTRY

NCT04063085 - The Assessment of the Use of Anti-Adhesion Agents to Prevent Pelvic Postoperative Adhesions | Biotech Hunter | Biotech Hunter